Expert Opinion | By Lloyd-Jones DM, Braun LT, Ndumele CE et al.
Clinical Trial | By Park DW, Ahn JM, Park SJ et al.
BACKGROUND - Comparative outcomes of coronary-artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for left main coronary artery (LMCA) disease were previously reported. However, data on very long-term (>10 years) outcomes are limited. OBJECTIVE - To compare 10-year outcomes after PCI and CABG for LMCA disease. METHOD...
Review Article | By D Capodanno, F Alfonso, GN Levine et al.
Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the atherothrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations. Prescribers of DAPT are confronted with a number of challenges that include selecting the appropriate P2Y12 inhibitor and determining the optimal duration of DAPT with the scope of minimizing the risk of ische...
Clinical Trial | By Collet JP, Silvain J, ARCTIC investigators.
BACKGROUND - Optimum duration of dual antiplatelet treatment (DAPT) after coronary stenting remains uncertain, with an unknown efficacy to safety ratio of extended treatment leading to discrepancies between international guidelines and clinical practice. We assessed whether DAPT continuation beyond 1 year after coronary stenting is beneficial. METHODS - This analysis was a planned extension of...
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
Clinical Trial | By Mauri L, Kereiakes DJ, DAPT Study Investigators.